{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:18:31Z","timestamp":1775251111365,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00280-018-3702-9","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:59:32Z","timestamp":1539651572000},"page":"61-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients"],"prefix":"10.1007","volume":"83","author":[{"given":"Brittney R.","family":"Starling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Barrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Farnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh","family":"Giovinazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Gehrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette T.","family":"Bensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"issue":"1","key":"3702_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1021\/nn900002m","volume":"3","author":"OC Farokhzad","year":"2009","unstructured":"Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16\u201320","journal-title":"ACS Nano"},{"issue":"12","key":"3702_CR2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"D Peer","year":"2007","unstructured":"Peer D, Karp JM, Hong S et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751\u2013760","journal-title":"Nat Nanotechnol"},{"issue":"1\u20132","key":"3702_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y et al (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65(1\u20132):271\u2013284","journal-title":"J Control Release"},{"issue":"3","key":"3702_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1634\/theoncologist.2007-0180","volume":"13","author":"WC Zamboni","year":"2008","unstructured":"Zamboni WC (2008) Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 13(3):248\u2013260","journal-title":"Oncologist"},{"issue":"1","key":"3702_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.nano.2013.07.005","volume":"10","author":"RF Schell","year":"2014","unstructured":"Schell RF, Sidone BJ, Caron WP et al (2014) Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomed Nanotechnol Biol Med 10(1):109\u2013117","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"3","key":"3702_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/08982104.2012.655285","volume":"22","author":"G Song","year":"2012","unstructured":"Song G, Wu H, Yoshino K et al (2012) Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. J Liposome Res 22(3):177\u2013192","journal-title":"J Liposome Res"},{"issue":"5","key":"3702_CR7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/clpt.2012.12","volume":"91","author":"WP Caron","year":"2012","unstructured":"Caron WP, Song G, Kumar P et al (2012) Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents. Clin Pharmacol Ther 91(5):802\u2013812","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3702_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/0091270010394851","volume":"52","author":"H Wu","year":"2011","unstructured":"Wu H, Ramanathan RK, Zamboni BA et al (2011) Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients With advanced malignancies. J Clin Pharmacol 52(2):180\u2013194","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3702_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.coi.2005.11.008","volume":"18","author":"DA Hume","year":"2006","unstructured":"Hume DA (2006) The mononuclear phagocyte system. Curr Opin Immunol 18(1):49\u201353","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"3702_CR10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","volume":"53","author":"SM Moghimi","year":"2001","unstructured":"Moghimi SM, Murray JC, Hunter AC (2001) Long-circulating and target specific nanoparticles: theory to practice. Pharmacol Rev 53(2):283\u2013318","journal-title":"Pharmacol Rev"},{"issue":"17","key":"3702_CR11","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625\u20131638","journal-title":"N Engl J Med"},{"issue":"7","key":"3702_CR12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.nano.2015.05.007","volume":"11","author":"G Song","year":"2015","unstructured":"Song G, Tarrant TK, White TF et al (2015) Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. Nanomed Nanotechnol Biol Med 11(7):1797\u20131807","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"23","key":"3702_CR13","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1158\/1078-0432.CCR-07-1035","volume":"13","author":"WC Zamboni","year":"2007","unstructured":"Zamboni WC, Strychor S, Joseph E et al (2007) Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res 13(23):7217\u20137223","journal-title":"Clin Cancer Res"},{"key":"3702_CR14","doi-asserted-by":"publisher","unstructured":"Song G, Moore S, Tarrant T et al (2012) Relationship between complement factors and CC chemokines and the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (Doxil) in patients with refractory epithelial ovarian cancer (EOC). In: Proceedings of 24th EORTC-NCI-AACR symposium on \u201cmolecular targets and cancer therapeutics. Abstract 126. https:\/\/doi.org\/10.1016\/S0959-8049(12)71924-X","DOI":"10.1016\/S0959-8049(12)71924-X"},{"issue":"5","key":"3702_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/clpt.2009.141","volume":"86","author":"WC Zamboni","year":"2009","unstructured":"Zamboni WC, Strychor S, Maruca L et al (2009) Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther 86(5):519\u2013526","journal-title":"Clin Pharmacol Ther"},{"key":"3702_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2147\/IJN.S62911","volume":"10","author":"H Wu","year":"2015","unstructured":"Wu H, Infante JR, Keedy VL et al (2015) Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Int J Nanomed 10:1201\u20131209","journal-title":"Int J Nanomed"},{"issue":"3","key":"3702_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00205515","volume":"18","author":"H Nielsen","year":"1984","unstructured":"Nielsen H (1984) Effect of cis-platinum on human blood monocyte function in vitro. Cancer Immunol Immunother 18(3):223\u2013225","journal-title":"Cancer Immunol Immunother"},{"key":"3702_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1677\/joe.0.0300277","volume":"30","author":"T Nicol","year":"1964","unstructured":"Nicol T, Bilbey D, Charles L et al (1964) Oestrogen: the natural stimulant of body defence. J Endocrinol 30:277\u2013291","journal-title":"J Endocrinol"},{"issue":"2","key":"3702_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1600-0897.1996.tb00015.x","volume":"35","author":"TC Chao","year":"1996","unstructured":"Chao TC, Phuangsab A, Van Alten PJ et al (1996) Steroid sex hormones and macrophage function: regulation of chemiluminescence and phagocytosis. Am J Reprod Immunol 35(2):106\u2013113","journal-title":"Am J Reprod Immunol"},{"key":"3702_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0074-7696(08)60202-8","volume":"25","author":"B Vernon-Roberts","year":"1969","unstructured":"Vernon-Roberts B (1969) The effects of steroid hormones on macrophage activity. Int Rev Cytol 25:131\u2013159","journal-title":"Int Rev Cytol"},{"key":"3702_CR21","first-page":"994","volume":"25","author":"J Ligibel","year":"2011","unstructured":"Ligibel J (2011) Obesity and breast cancer. Oncology 25:994\u20131000","journal-title":"Oncology"},{"issue":"6","key":"3702_CR22","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/en.2009-0070","volume":"150","author":"MP Cleary","year":"2009","unstructured":"Cleary MP, Grossmann ME (2009) Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150(6):2537\u20132542","journal-title":"Endocrinology"},{"issue":"2","key":"3702_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1207\/S15327914NC4402_02","volume":"44","author":"BS Connolly","year":"2002","unstructured":"Connolly BS, Barnett C, Vogt KN et al (2002) A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer 44(2):127\u2013138","journal-title":"Nutr Cancer"},{"issue":"3","key":"3702_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1467-789X.2003.00108.x","volume":"4","author":"M Harvie","year":"2003","unstructured":"Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157\u2013173","journal-title":"Obes Rev"},{"issue":"1","key":"3702_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1600-065X.2012.01151.x","volume":"249","author":"AR Johnson","year":"2012","unstructured":"Johnson AR, Justin Milner J, Makowski L (2012) The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev 249(1):218\u2013238","journal-title":"Immunol Rev"},{"issue":"3","key":"3702_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jama.2009.2014","volume":"303","author":"KM Flegal","year":"2010","unstructured":"Flegal KM, Carroll MD, Ogden CL et al (2010) Prevalence and trends in obesity among US adults, 1999\u20132008. JAMA 303(3):235\u2013241","journal-title":"JAMA"},{"issue":"7","key":"3702_CR27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2337\/diacare.15.7.815","volume":"15","author":"MI Harris","year":"1992","unstructured":"Harris MI, Klein R, Welborn TA et al (1992) Onset of NIDDM occurs at least 4\u20137\u00a0year before clinical diagnosis. Diabetes Care 15(7):815\u2013819","journal-title":"Diabetes Care"},{"issue":"5","key":"3702_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277\u2013300","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3702_CR29","first-page":"95","volume":"28","author":"E Steiner","year":"2007","unstructured":"Steiner E, Plata K, Interthal C et al (2007) Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients. Eur J Gynaecol Oncol 28(2):95\u201397","journal-title":"Eur J Gynaecol Oncol"},{"issue":"8","key":"3702_CR30","first-page":"3940","volume":"43","author":"MJ Reed","year":"1983","unstructured":"Reed MJ, Cheng RW, Noel CT et al (1983) Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 43(8):3940\u20133943","journal-title":"Cancer Res"},{"issue":"6","key":"3702_CR31","first-page":"649","volume":"4","author":"SE Hankinson","year":"1995","unstructured":"Hankinson SE, Manson JE, Willett WC et al (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2\u20133-year period. Cancer Epidemiol Biomark Prev 4(6):649\u2013654","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"3702_CR32","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/annonc\/mdl484","volume":"18","author":"E Andreopoulou","year":"2007","unstructured":"Andreopoulou E, Gaiotti D, Kim E et al (2007) Pegylated liposomal doxorubicin HCL (PLD; Caelyx\/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 18(4):716\u2013721","journal-title":"Ann Oncol"},{"issue":"9","key":"3702_CR33","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","volume":"20","author":"FM Muggia","year":"2002","unstructured":"Muggia FM, Blessing JA, Sorosky J et al (2002) Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study. J Clin Oncol 20(9):2360\u20132364","journal-title":"J Clin Oncol"},{"issue":"3","key":"3702_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.critrevonc.2005.11.002","volume":"58","author":"A Gadducci","year":"2006","unstructured":"Gadducci A, Cosio S, Genazzani AR (2006) Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 58(3):242\u2013256","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"3702_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/0895-4356(91)90218-X","volume":"44","author":"DS Gray","year":"1991","unstructured":"Gray DS, Fujioka K (1991) Use of relative weight and Body Mass Index for the determination of adiposity. J Clin Epidemiol 44(6):545\u2013550","journal-title":"J Clin Epidemiol"},{"key":"3702_CR36","doi-asserted-by":"publisher","unstructured":"WHO (2000) Obesity: preventing and managing the global epidemic. Report of a WHO Consultation, vol\u00a0894. https:\/\/doi.org\/10.1016\/S0140-6736(57)91352-1","DOI":"10.1016\/S0140-6736(57)91352-1"},{"key":"3702_CR37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1124\/jpet.113.208801","volume":"347","author":"WP Caron","year":"2013","unstructured":"Caron WP, Lay JC, Fong AM et al (2013) Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. J Pharmacol Exp Ther 347:599\u2013606","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"3702_CR38","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/1055-9965.EPI-12-0485","volume":"21","author":"W Demark-Wahnefried","year":"2012","unstructured":"Demark-Wahnefried W, Platz EA, Ligibel JA et al (2012) The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cospons Am Soc Prev Oncol 21(8):1244\u20131259","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cospons Am Soc Prev Oncol"},{"issue":"1","key":"3702_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-011-1664-2","volume":"69","author":"NM La-Beck","year":"2012","unstructured":"La-Beck NM, Zamboni BA, Gabizon A et al (2012) Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69(1):43\u201350","journal-title":"Cancer Chemother Pharmacol"},{"key":"3702_CR40","doi-asserted-by":"publisher","unstructured":"Song G, Terrant TK, Barrow DA et al (2012) The effect of CC chemokine ligand-2 (CCL2\/MCP-1) and CC chemokine ligand-5 (CCL5\/RANTES) on the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. In: Proceedings of American association for cancer research. Abstract 754. https:\/\/doi.org\/10.1158\/1538-7445.AM2012-754","DOI":"10.1158\/1538-7445.AM2012-754"},{"key":"3702_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.steroids.2015.03.016","volume":"103","author":"J Li","year":"2015","unstructured":"Li J, Papadopoulos V, Vihma V (2015) Steroid biosynthesis in adipose tissue. Steroids 103:89\u2013104","journal-title":"Steroids"},{"issue":"3","key":"3702_CR42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00280-015-2945-y","volume":"77","author":"H Giovinazzo","year":"2016","unstructured":"Giovinazzo H, Kumar P, Sheikh A et al (2016) Technetium Tc 99 m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. Cancer Chemother Pharmacol 77(3):565\u2013573","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3702_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","volume":"95","author":"AN Gordon","year":"2004","unstructured":"Gordon AN, Tonda M, Sun S et al (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95(1):1\u20138","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3702_CR44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ygyno.2005.05.016","volume":"98","author":"HD Homesley","year":"2005","unstructured":"Homesley HD, Blessing JA, Sorosky J et al (2005) Phase II trial of liposomal doxorubicin at 40 mg\/m(2) every 4\u00a0weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 98(2):294\u2013298","journal-title":"Gynecol Oncol"},{"issue":"13","key":"3702_CR45","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","volume":"30","author":"JJ Griggs","year":"2012","unstructured":"Griggs JJ, Mangu PB, Temin S et al (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30(13):1553\u20131561","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3702-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:08:14Z","timestamp":1775246894000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3702-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3702"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3702-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Brittney Roberts Starling has no conflicts of interest to report. Parag Kumar has no conflicts of interest to report. Andrew T. Lucas has no conflicts of interest to report. David Barrow has no conflicts of interest to report. Laura Farnan has no conflicts of interest to report. Laura Hendrix has no conflicts of interest to report. Hugh Giovinazzo has no conflicts of interest to report. Gina Song has no conflicts of interest to report. Paola Gehrig has no conflicts of interest to report. Jeannette T. Bensen has no conflicts of interest to report. William C. Zamboni has no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Studies were approved by the University of North Carolina Institutional Review Board (UNC IRB# 08-1204 & UNC IRB# 14-2078).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}